Skip to main content

Table 3 Serum glucose and lipid profile levels distribution among different combinations of HAART taken by study participants at Burayu Health Center, Addis Ababa, Ethiopia, 2012

From: Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study

Glucose/lipid profile

NVP versus EFV based combination of ARVs

P-value

NVP (n=65)

EFV (n=61)

N (%)

N (%)

Glucose

≤110

60(92.3)

56(91.8)

0.917

>110

5(7.7)

5(8.2)

Triglyceride

<150

37(56.9)

30(49.2)

0.384

≥150

28(43.1)

31(50.8)

Total cholesterol

<200

37(56.9)

36(59)

0.812

≥200

28(43.1)

25(41)

HDL-cholesterol

<40

28(43.1)

36(59)

0.074

≥40

37(56.9)

25(41)

LDL-cholesterol

<130

48(73.8)

49(80.3)

0.388

≥130

17(26.2)

12(19.7)

Glucose/lipid profile

D4T versus AZT based combination of ARVs

P-value

D4T (n=47)

AZT (n=67)

N (%)

N (%)

Glucose

≤110

40(85.1)

64(95.5)

0.053

>110

7(14.9)

3(4.5)

Triglyceride

<130

25(53.2)

35(52.2)

0.920

≥130

22(46.8)

32(47.8)

Total cholesterol

<200

28(59.6)

39(58.2)

0.884

≥200

19(40.4)

28(41.8)

HDL-cholesterol

<40

26(55.3)

33(49.3)

0.524

≥40

21(44.7)

34(50.7)

LDL-cholesterol

<130

37(78.7)

53(79.1)

0.961

≥130

10(21.3)

14(20.9)

  1. AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; p, significance level.